Comparison of Seroflu and Seretide Inhalers on Spirometry Criteria and Clinical Symptoms in Patients with Severe and Moderate Asthma

Asthma is one of the most prevalent chronic respiratory diseases which has become more prevalent over the past three decades. Seroflo and Seretide are inhalers that contain fluticasone (an anti-inflammatory corticosteroid) and salmeterol (a long-acting bronchodilator). This study aimed to compare the effects of Seroflo and Seretide nasal sprays on spirometry criteria and clinical symptoms in pediatric patients with moderate to severe asthma.

A retrospective study was performed using the medical records of 42 patients aged 6-15 years with a history of moderate-to-severe persistent asthma who were treated with Seroflo (group A)and Seretide (group B) inhalers in Shahid Motahari Hospital (affiliated with Urmia University of Medical Sciences). Data, including age, gender, clinical symptoms (coughs and shortness of breath), and spirometry variables were documented in pre-made checklists. Data analysis was carried out in SPSS V22.

Changes in PEF and FEV1 (parameters of treatment responses) were statistically significant in both groups (P<0.05), but no significant differences were observed in these parameters between the two groups (P>0.05). In this study, treatment with Seroflo caused more significant relief in clinical symptoms, including coughs, intermittent shortness of breath, daily attacks, and wheezing compared to Seretide after one and three months of treatment (P<0.05).

This study suggested that Seroflo and Seretide inhalers improved the spirometry indices to a similar degree, but treatment with Seroflo relieved the patients’ clinical symptoms more than Seretide.